CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company’s primary product is Neutrolin, a catheter lock solution, which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. It has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC, a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin, which is in the pre-clinical stage of development.
